TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Beamtree Holdings Ltd ( (AU:BMT) ) has issued an announcement.
Beamtree Holdings Limited reported a 9% increase in recurring revenue for Q1 FY26, driven by growth across all product lines, including a significant clinical coding audit contract in Singapore and new contracts for its PICQ Audit and Rippledown solutions. The company is advancing its strategic roadmap with international market expansions, including the deployment of an autonomous clinical coding solution and a collaboration with the NHS Confederation in the UK. The appointment of Stuart MacDonald as a Non-Executive Director is expected to aid in scaling Beamtree’s product offerings and international growth. Despite a reduction in cash reserves due to software investment, Beamtree remains confident in its ability to deliver continued financial improvement through disciplined cost management and strategic capital allocation.
The most recent analyst rating on (AU:BMT) stock is a Buy with a A$0.60 price target. To see the full list of analyst forecasts on Beamtree Holdings Ltd stock, see the AU:BMT Stock Forecast page.
More about Beamtree Holdings Ltd
Beamtree Holdings Limited is a leading provider of AI decision support and data insights solutions for the healthcare sector. The company focuses on turning data into insights and action through automation, aiming to improve patient outcomes globally. Beamtree offers a range of analytics across four key product segments, supporting healthcare providers with smart tools to solve real-world problems.
Average Trading Volume: 276,721
Technical Sentiment Signal: Sell
Current Market Cap: A$61.03M
See more insights into BMT stock on TipRanks’ Stock Analysis page.